Use of psychopharmaceuticals during COVID-19 treatment

Abstract

No specific cure has been found since the beginning of the COVID-19 pandemic. In the treatment of infection caused by SARS-CoV-2 virus, therapeutic protocols include drugs of different groups: antiviral drugs, antibodies, antibiotics, anti-inflammatory drugs, etc. It can be expected that a certain number of patients who are receiving therapy with psychopharmacotherapy will get sick from COVID-19, but we also know that the infection itself has certain psychological manifestations. Due to the above, the use of psychopharmacotherapy together with other drugs in the therapy of COVID-19 is sometimes unavoidable. Co-administering these drugs has to be with caution due to the potential prolongation of the QTc interval, drug interactions at the CYP enzyme level, and the associated potential for agranulocytosis.